Hyderabad, in recent times, has emerged as a major scientific and R&D hub for Pharma and Life Sciences sector. It is rightly recognized as the Vaccine Hub of India and the world, producing about 33% of global vaccines dosages.
The State Government has set has set out an ambitious vision for the sector, through leveraging the existing strengths to create additional 4,00,000 jobs with a targeted investment of USD 100 Billion over next 10 years.
The government has launched various initiatives including Genome Valley 2.0 Hyderabad Pharma City, Medical Devices Park, Life sciences Profiling, support for incubators, Life Sciences infrastructure fund, and BioAsia to supplement the support required for this ambitious endeavour.
Minister for IT, Industries & Commerce, K T Rama Rao announced the establishment of a state-of-the-art B-HUB, which will have a scale-up manufacturing facility for biopharma based R&D at Genome Valley, Hyderabad. The announcement was made in Hyderabad post a detailed discussion.
The proposed B-Hub facility, with an estimated project cost of INR 60 Crores, will be set up through Public Private Partnership in Genome Valley which is India’s first organized cluster for life sciences R&D and clean manufacturing activities.
B-Hub will be a first of its kind initiative in the country, aimed at providing much-needed support to the biopharma R&D activities featuring a scale-up manufacturing facility along with a turnkey incubator / lab space module at GLP grade within a built-up area of 40,000 Square Feet.
K T R said, “With Indian companies aggressively embarking on the global biosimilars opportunity, a Biopharma scale-up facility will help them leapfrog in their endeavour, while reducing the time to market. Inadequacy of scale-up infrastructure and funding is pushing cream of biopharma ventures to re-domicile themselves in different parts of the world.
Hyderabad being the Life Sciences capital of the Country, we have taken the lead by conceptualizing B-Hub, a biopharma scale-up lab with separate areas for cell-line development, media screening, clone selection, upstream and downstream process development and small-scale production (100L) for pre-clinical studies.”
“Genome Valley is a very unique cluster and the kind of cutting-edge scientific efforts happening in Genome Valley is just unmatchable by any other cluster in India and perhaps Asia. With over 200 companies, Genome Valley is home to companies with varied capabilities.
